Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Merck & Co., Inc. (MRK) vs SiTime Corporation (SITM) Price & Performance

Merck & Co., Inc.Trade
SiTime CorporationTrade

Price performance (Past 24H)

Key statistics

Merck & Co., Inc. vs SiTime Corporation — how do they compare? Merck & Co., Inc. trades at $133.57 (market cap $321.77B), while SiTime Corporation trades at $699.14 (market cap $20.05B). The key difference: Merck & Co., Inc. is far larger — about 16× SiTime Corporation's market cap, and Merck & Co., Inc. pays a 2.61% dividend while SiTime Corporation pays none. Which is the better fit depends on your goals.

MRKSITM
Market Cap
$321.77B$20.05B
Sector
HealthTechnology
52-Week High
$131.84$901.60
52-Week Low
$77.60$212.77
Enterprise Value
$368.53B$19.45B
Dividend Yield
2.61%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Merck & Co., Inc.

Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.

Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.

SiTime Corporation

SITM trades at $700.42, up 1.52% today, with a bullish technical outlook and strong analyst consensus. Recent Q2 2026 earnings beat estimates with EPS of $2.34 versus $1.95 expected, driven by 127% revenue growth from AI infrastructure demand. The stock shows robust institutional interest and positive media coverage highlighting AI timing growth.

Outlook is positive with a consensus price target of $870, but risks include high valuation multiples (P/E 1,111.15, P/S 38.1) and integration challenges from the Renesas acquisition. Earnings momentum and AI exposure support upside, yet execution and premium pricing warrant caution for investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK

About SiTime Corporation

SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.

Read more on SITM